NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers are considering increasing NHS payments to pharmaceutical companies by up to 25% to resolve ongoing disputes with the industry and the Trump administration. This move comes after concerns that the standoff has led to companies reducing their investments in the UK. By potentially raising these payments, the government aims to ensure a stable supply of medicines while addressing the financial pressures faced by drugmakers. This decision could have significant implications for healthcare funding and the pharmaceutical landscape in the UK.